Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Corona Remedies's Enterprise Value is ₹129,993 Mil.
Corona Remedies's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ₹1,751 Mil. Therefore, Corona Remedies's EV-to-EBIT ratio for today is 74.25.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Corona Remedies's Enterprise Value is ₹129,993 Mil.
Corona Remedies's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹2,037 Mil. Therefore, Corona Remedies's EV-to-EBITDA ratio for today is 63.81.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Corona Remedies's Enterprise Value is ₹129,993 Mil.
Corona Remedies's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was ₹10,418 Mil. Therefore, Corona Remedies's EV-to-Revenue ratio for today is 12.48.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Corona Remedies's Enterprise Value is ₹129,993 Mil.
Corona Remedies's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹126 Mil. Therefore, Corona Remedies's EV-to-FCF ratio for today is 1,030.79.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Corona Remedies (NSE:CORONA) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Corona Remedies's current Enterprise Value is ₹129,993 Mil.
Corona Remedies's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,751 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Corona Remedies's current Enterprise Value is ₹129,993 Mil.
Corona Remedies's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹2,037 Mil.
Corona Remedies's current Enterprise Value is ₹129,993 Mil.
Corona Remedies's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹10,418 Mil.
Corona Remedies's current Enterprise Value is ₹129,993 Mil.
Corona Remedies's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹254 Mil.
Corona Remedies's current Enterprise Value is ₹129,993 Mil.
Corona Remedies's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹126 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corona Remedies Enterprise Value Related Terms
Corona Remedies Enterprise Value Historical Data
* Premium members only.
The historical data trend for Corona Remedies's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:CORONA vs LLY, JNJ, ABBV: Enterprise Value Comparison
For the Drug Manufacturers - General subindustry, Corona Remedies's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corona Remedies Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Corona Remedies's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Corona Remedies's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Corona Remedies's Enterprise Value for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of ₹129,993 Mil mean?
Corona Remedies (NSE:CORONA) has a Enterprise Value of ₹129,993 Mil as of Aug. 01, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Corona Remedies and its competitors.
Is Corona Remedies' Enterprise Value too high?
Corona Remedies' current Enterprise Value is ₹129,993 Mil. Overall, Corona Remedies has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Corona Remedies' Enterprise Value compare to LLY and JNJ?
Corona Remedies' Enterprise Value of ₹129,993 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Corona Remedies and its competitors. Corona Remedies's current Enterprise Value is ₹129,993 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corona Remedies stock overvalued right now?
Corona Remedies (NSE:CORONA) has a current Enterprise Value of ₹129,993 Mil. The current Enterprise Value is ₹129,993 Mil. Corona Remedies' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Corona Remedies (NSE:CORONA), the current Enterprise Value is ₹129,993 Mil as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Corona Remedies Ltd is mainly engaged in the business of manufacturing, trading and marketing of Pharmaceutical products. It is engaged in developing, manufacturing and marketing products in women's healthcare, cardio-diabetes, pain management, urology and other segments, such as Vitamin Minerals and Nutrients(VMN), gastrointestinal and respiratory therapies. The company's brands are B-29, myoril, Tricium, Cortel, and Obimet. The Company has only one reportable business segment i.e. Pharmaceuticals. The company has presence in India as well as Outside India. The company generates majority of revenue from India.
18GF Score
Get the complete analysis for NSE:CORONA
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CORONA has been successfully added to your 
